Order Article Reprints

Barrios-Bernal P, Hernandez-Pedro N, Orozco-Morales M, Viedma-Rodríguez R, Lucio-Lozada J, Avila-Moreno F, Cardona AF, Rosell R, Arrieta O. Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells. Pharmaceuticals. 2022; 15(3):381. https://doi.org/10.3390/ph15030381

Barrios-Bernal, Pedro, Norma Hernandez-Pedro, Mario Orozco-Morales, Rubí Viedma-Rodríguez, José Lucio-Lozada, Federico Avila-Moreno, Andrés F. Cardona, Rafael Rosell, and Oscar Arrieta. 2022. "Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells" Pharmaceuticals 15, no. 3: 381. https://doi.org/10.3390/ph15030381

Barrios-Bernal, P., Hernandez-Pedro, N., Orozco-Morales, M., Viedma-Rodríguez, R., Lucio-Lozada, J., Avila-Moreno, F., Cardona, A. F., Rosell, R., & Arrieta, O. (2022). Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells. Pharmaceuticals, 15(3), 381. https://doi.org/10.3390/ph15030381